Edaravone is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Edaravone (brand name: Radicava; also known as MCI-186; chemical name: 3-methyl-1-phenyl-2-pyrazolin-5-one) is a pyrazolone-class free radical scavenger approved for the treatment of [amyotrophic lateral sclerosis (ALS)[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX--. The drug was first approved in Japan in 2001 for the treatment of acute ischemic stroke, and subsequently received FDA approval in May 2017 as the second drug ever approved for ALS treatment, following [riluzole[/treatments/[riluzole[/treatments/[riluzole[/treatments/[riluzole--TEMP--/treatments)--FIX-- 1(https://pmc.ncbi.nlm.nih.gov/articles/PMC5737249/) 2(https://go.drugbank.com/drugs/DB12243). An oral suspension formulation (Radicava ORS) was approved by the FDA in May 2022, providing a more convenient alternative to the original intravenous formulation 3(https://www.tandfonline.com/doi/full/10.1080/14737175.2023.2251687).
Edaravone's primary mechanism of action involves scavenging free radicals and reducing [oxidative stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX--, which is believed to contribute to [motor neuron] degeneration in ALS. While the exact mechanism by which edaravone slows ALS progression is not fully understood, its strong antioxidant properties are thought to protect [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--, [astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX--, and vascular endothelial cells from oxidative damage 4(https://pmc.ncbi.nlm.nih.gov/articles/PMC2797401/) 5(https://pmc.ncbi.nlm.nih.gov/articles/PMC8868074/). Originally developed by Mitsubishi Chemical Industries (now Mitsubishi Tanabe Pharma), edaravone represents a distinct pharmacological approach to ALS treatment compared to the glutamate-modulating [riluzole[/treatments/[riluzole[/treatments/[riluzole[/treatments/[riluzole--TEMP--/treatments)--FIX--, and the two drugs are frequently used together in clinical practice.
Edaravone functions as a potent free radical scavenger with the ability to neutralize both hydroxyl radicals (•OH) and peroxyl radicals (ROO•). The drug's pyrazolone ring structure enables it to donate electrons to free radicals, converting them to more stable, less reactive species. This antioxidant activity occurs through a one-electron transfer mechanism, where edaravone is oxidized to form an edaravone radical, which is subsequently metabolized to inactive products 4(https://pmc.ncbi.nlm.nih.gov/articles/PMC2797401/) 6(https://pmc.ncbi.nlm.nih.gov/articles/PMC6741743/).
In the context of ALS, [oxidative stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX-- is a well-established contributor to [motor neuron] degeneration. Mutations in the [SOD1[/proteins/[sod1-protein[/proteins/[sod1-protein[/proteins/[sod1-protein--TEMP--/proteins)--FIX-- gene—found in approximately 2% of all ALS cases—directly impair the cell's primary antioxidant defense system, leading to accumulation of [reactive oxygen species ([ROS[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX-- 7(https://pmc.ncbi.nlm.nih.gov/articles/PMC5737249/). Edaravone combats this oxidative burden through several complementary pathways:
Beyond direct radical scavenging, edaravone activates the Nrf2 (Nuclear factor erythroid 2-related factor 2) signaling pathway, a master regulator of cellular antioxidant responses. Activation of Nrf2 induces the expression of a battery of cytoprotective genes, including heme oxygenase-1 (HO-1), NAD(P)H quinone dehydrogenase 1 (NQO1), and glutathione S-transferases, amplifying the cell's endogenous antioxidant capacity 5(https://pmc.ncbi.nlm.nih.gov/articles/PMC8868074/).
Edaravone has been shown to exert protective effects on [mitochondrial] function. In neurodegenerative diseases including ALS, mitochondrial dysfunction leads to increased [ROS[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX-- production, impaired energy metabolism, and activation of [apoptotic] pathways. Edaravone preserves mitochondrial membrane potential, reduces mitochondrial [ROS[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX-- generation, and prevents the release of cytochrome c, thereby inhibiting the intrinsic apoptotic cascade 5(https://pmc.ncbi.nlm.nih.gov/articles/PMC8868074/).
Edaravone protects components of the neurovascular unit—including [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--, [astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX--, [pericytes[/entities/[pericytes[/entities/[pericytes[/entities/[pericytes--TEMP--/entities)--FIX--, and endothelial cells—from oxidative damage. This broad-spectrum protection is particularly relevant in ALS, where [Blood-Brain Barrier ([BBB[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier--TEMP--/entities)--FIX-- integrity is compromised and neurovascular dysfunction contributes to disease progression 4(https://pmc.ncbi.nlm.nih.gov/articles/PMC2797401/).
Edaravone also demonstrates anti-inflammatory properties. It suppresses the production of pro-inflammatory cytokines and reduces activation of [microglia[/https://pmc.ncbi.nlm.nih.gov/articles/PMC5324974/[/https://pmc.ncbi.nlm.nih.gov/articles/PMC5324974/[/https://pmc.ncbi.nlm.nih.gov/articles/PMC5324974/--TEMP--/https://pmc.ncbi.nlm.nih.gov)--FIX--.
Edaravone is rapidly distributed after intravenous administration, with a plasma half-life of approximately 4.5–6 hours. The drug is highly protein-bound (92%) and is primarily metabolized through glucuronide conjugation and sulfate conjugation. Edaravone and its metabolites are excreted mainly through the urine 2(https://go.drugbank.com/drugs/DB12243).
The oral suspension formulation (Radicava ORS) contains edaravone in a lipid-based formulation that enhances gastrointestinal absorption. The oral formulation achieves comparable bioavailability to the intravenous formulation and allows for once-daily administration at home, significantly improving convenience for patients 3(https://www.tandfonline.com/doi/full/10.1080/14737175.2023.2251687).
The FDA-approved dosing regimen follows a cyclical on/off pattern:
The pivotal trial that led to FDA approval was a randomized, double-blind, placebo-controlled study conducted in Japan (Study MCI186-19). The trial enrolled 137 patients with ALS and demonstrated that edaravone significantly slowed the decline in the ALS Functional Rating Scale-Revised (ALSFRS-R) score compared to placebo over a 24-week treatment period 1(https://pmc.ncbi.nlm.nih.gov/articles/PMC5737249/) 9(https://www.radicavahcp.com/efficacy/).
Key results:
However, the trial enrolled a relatively narrow ALS population with specific inclusion criteria (definite or probable ALS, FVC ≥80%, disease duration ≤2 years, ALSFRS-R score ≥2 on all items), leading to questions about generalizability to the broader ALS population 1(https://pmc.ncbi.nlm.nih.gov/articles/PMC5737249/).
Subsequent post-hoc analyses of the pivotal trial data using novel statistical methods (latent class analysis) have suggested that edaravone treatment results in slower ALSFRS-R decline compared to placebo across multiple predicted disease trajectories, not only in the narrowly defined pivotal trial population 10(https://www.sciencedirect.com/science/article/pii/S0022510X2400426X).
The REFINE-ALS (Radicava/Edaravone Findings in Biomarkers from ALS) study is an ongoing Phase 4, prospective, multicenter, observational study designed to characterize biomarkers associated with edaravone treatment and to better understand its mechanism of action in ALS. As of mid-2023, the study had enrolled 73 participants. The study collects biofluid samples (blood, CSF) and clinical outcomes data, which are matched with the Answer ALS biorepository to identify response biomarkers 11(https://www.neurology.org/doi/10.1212/CPJ.0000000000000968) 12(https://clinicaltrials.gov/study/NCT04259255).
Ongoing Phase 3 studies (MT-1186-A03) are evaluating the long-term safety and tolerability of the oral formulation over 96 weeks. These studies also examined whether a simplified once-daily dosing regimen (without the cyclical on/off pattern) might offer superior efficacy, though at 48 weeks the once-daily regimen did not demonstrate superiority over the approved on/off dosing schedule 13(https://www.mdaconference.org/abstract-library/phase-3-open-label-safety-extension-study-of-investigational-oral-edaravone-administered-over-96-weeks-in-patients-with-als-mt-1186-a03/).
Edaravone is generally well tolerated. The most common adverse effects include:
Hepatic and renal function should be monitored during treatment, as edaravone is primarily metabolized and excreted through these organs.
Edaravone is approved for the treatment of ALS in the United States, Japan, South Korea, Canada, and several other countries. In clinical practice, edaravone is often used in combination with [riluzole[/treatments/[riluzole[/treatments/[riluzole[/treatments/[riluzole--TEMP--/treatments)--FIX--, as the two drugs have complementary mechanisms of action—riluzole targeting [excitotoxicity[/entities/[excitotoxicity[/entities/[excitotoxicity[/entities/[excitotoxicity--TEMP--/entities)--FIX-- and edaravone targeting [oxidative stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX-- 1(https://pmc.ncbi.nlm.nih.gov/articles/PMC5737249/).
In Japan and several Asian countries, edaravone has been approved for the treatment of acute ischemic stroke since 2001. Its neuroprotective effects in stroke are attributed to the same free radical scavenging properties that underpin its ALS indication, as ischemia-reperfusion injury generates substantial oxidative stress in brain tissue 6(.
Research is ongoing into potential applications of edaravone in other neurodegenerative conditions, including [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- and [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--, where [oxidative stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX-- plays a significant pathogenic role. Preclinical studies suggest edaravone may protect against [amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- and [alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein--TEMP--/proteins)--FIX---mediated toxicity, though clinical evidence in these indications remains limited 5(https://pmc.ncbi.nlm.nih.gov/articles/PMC8868074/).
The study of Edaravone has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.